A study found that 2 or 3 doses of the COVID-19 vaccine reduced the rate of long COVID among Italian health care workers.
The health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in a new study in the peer-reviewed Journal of Medical Economics.Read More
A Phase 2 clinical trial to evaluate second COVID booster shots has begun enrolling adult participants in the United States. The COVID-19 Variant Immunologic Landscape (COVAIL) trial, sponsored by the NIAID, aims to understand if different vaccine regimens—prototype and variant vaccines alone and in combinations—can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.Read More
Pfizer Inc and BioNTech SE have submitted an application for US FDA authorization of a 10-µg booster dose of its pediatric COVID booster for children age 5 through 11 years old.Read More
A clinical trial by the NIAID will study rare but potentially serious systemic allergic reactions to COVID vaccines.Read More
A large increase in skin bacteria in mice inoculated with the smallpox vaccine may enhance the immune response, according to a study published in Plos Pathogens.Read More
The novel CoVac-1 COVID vaccine induced T-cell immune responses in 93% of patients with B-cell deficiencies, including many patients with leukemia and lymphoma.Read More
A third COVID vaccine dose benefitted most immunocompromised people with a blood cancer called multiple myeloma, according to a fast-tracked study in Cancer Cell.Read More